Peroxisome proliferator-activated receptor γ (PPARγ) is a widely expressed ligand-
modulated transcription factor that governs the expression of genes involved in …

Chemotherapy-induced neuropathic pain (CINP) is one of the most severe side effects of
anticancer agents, such as platinum-and taxanes-derived drugs (oxaliplatin, cisplatin …

Traumatic injury or disease of the spinal cord and brain elicits multiple cellular and
biochemical reactions that together cause or are associated with neuropathology …

Painful peripheral neuropathy is a dose-limiting side effect of cisplatin treatment. Using a
murine model of cisplatin-induced hyperalgesia, we determined whether a PPARg synthetic …

Chronic pain is a common cause of disability worldwide and remains a global health and
socio‐economic challenge. Current analgesics are either ineffective in a significant …

Repeated administration of peroxisome proliferator–activated receptor gamma (PPARg)
agonists reduces neuropathic pain-like behavior and associated changes in glial activation …

Pioglitazone, an agonist at peroxisome proliferator-activated receptor gamma, is FDA-
approved for the treatment of insulin resistance in type 2 diabetes. Numerous studies in …

Chronic pain presents a widespread and intractable medical problem. While numerous
pharmaceuticals are used to treat chronic pain, drugs that are safe for extended use and …

A growing number of studies reported that rosiglitazone (a PPARgamma agonist) could
ameliorate the painful state and prevent stress-induced depression. However, whether …

Diabetic neuropathy (DN) is a common complication of diabetes mellitus (DM).
Pathophysiology of DN includes inflammation and changes in expression and function of …